FOLH1 and prostate carcinoma: Pasotuxizumab, a bispecific T-cell engager developed to target prostate cancer cells via PSMA, was given to 47 patients with advanced prostate cancer either subcutaneously or through continuous IV (cIV) in a phase 1 study (NCT01723475) [132].